In an interview for Becker’s Hospital Review, President Rita Numerof discusses the controversy surrounding the price of EpiPens and why Mylan may not deserve all the backlash it’s endured.

“It’s not about putting in price controls; it’s about stimulating good competition. The pharmaceutical industry needs a more market-sensitive regulatory apparatus in the FDA, which will encourage more competition and result in better regulation and pricing balance.”

Numerof’s comments appeared in Is Mylan really the bad guy? 4 thoughts from a leading healthcare strategist on the big picture of pharma price hikes.